Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
Yoichi NakamuraSoichiro HozawaHironori SagaraHiroyuki OhbayashiLaurie A LeeJodie CrawfordJun TamaokiTakanobu NishiAndrew FowlerPublished in: Current medical research and opinion (2021)
FF/UMEC/VI is an effective option with a favorable risk-benefit profile in Japanese patients with uncontrolled moderate or severe asthma on ICS/LABA.